Company
Management
Christophe Thurieau
Chief Executive Officer
Executive Director of Research Institute and Global Head of External Research at Servier- In his rol… Read moree at Servier , Dr Christophe Thurieau is leading Servier’s Research centers and as head of external Research he is responsible for World Wide Research hubs to establish external strategic partnerships in R&D. Before joining Servier in April 2017 Dr Christophe Thurieau worked at Ipsen from 1996 to 2017. After different increasing roles and responsibilities within Research and Development at Ipsen, he was since 2009 President Ipsen Innovation and Senior Vice –President Global Scientific Affairs at Ipsen. He has authored more than 30 original research articles in international peer-reviewed scientific journal and holds 25 patents. Dr Christophe Thurieau obtained pre and post-doctoral training at Harvard medical school, Boston (U.S.) and received his Ph.D. in biochemistry from University Pierre and Marie Curie, Paris VI in 1988.
Rikke Bolding Jensen, M.Sc, Ph.D,
Director, Head of CMC Biologics
Rikke Bolding Jensen, M.Sc, Ph.D, is a Danish national, born in 1969. She joined Symphogen in 2014.… Read more
Before joining Symphogen, Rikke Bolding Jensen served development and CMC project management positions in Nycomed/Takeda and Maxygen.
Before joining Symphogen, Rikke Bolding Jensen served development and CMC project management positions in Nycomed/Takeda and Maxygen.
Malin Carlsson, MD, Ph.D
General Manager, Head of Symphogen (Direktør)
Malin Carlsson, MD, Ph.D, is a Swedish-national, born in 1968. She joined Symphogen in 2023
… Read moreBefore joining Symphogen, Malin Carlsson served as Executive Vice President and Chief Operating Officer in Alligator Biosciences (Sweden) and she brings 20 years of research experience in immunology and more than 15 years of experience in early and clinical stage drug development and translational medicine. Malin Carlsson has held various leadership positions in medium and large pharmaceutical companies such as AstraZeneca, Nycomed/Takeda and Ferring Pharmaceutical.
… Read moreBefore joining Symphogen, Malin Carlsson served as Executive Vice President and Chief Operating Officer in Alligator Biosciences (Sweden) and she brings 20 years of research experience in immunology and more than 15 years of experience in early and clinical stage drug development and translational medicine. Malin Carlsson has held various leadership positions in medium and large pharmaceutical companies such as AstraZeneca, Nycomed/Takeda and Ferring Pharmaceutical.
Lisbet Løschenkohl
SVP, Head of People & Facility
Lisbet Løschenkohl is a Danish national, born in 1967. She joined Symphogen in 2008 as Head of HR. … Read more
Before joining Symphogen, Lisbet Løschenkohl headed the HR and Facility function in Rheosciene and Center for Clinical and Basic Research.
Before joining Symphogen, Lisbet Løschenkohl headed the HR and Facility function in Rheosciene and Center for Clinical and Basic Research.
Claus Haase, Ph.D
SVP, Head of Biologic Drug Design
Claus Haase, Ph.D, is a Danish national, born in 1976.
He joined Symphogen in 2023 and has p… Read morereviously held leadership positions in Novo Nordisk A/S, Ferring Pharmaceuticals and LEO Pharma.
He joined Symphogen in 2023 and has p… Read morereviously held leadership positions in Novo Nordisk A/S, Ferring Pharmaceuticals and LEO Pharma.
Michael Herbst
VP, Finance and Procurement
Michael Herbst is a Danish national, born in 1972. He joined Symphogen in 2023.
He ho… Read morelds a Graduate Diploma in Business Administration (Finance & Management) from Copenhagen Business School. Prior to joining Symphogen, Michael Herbst held various management positions in finance and administration in companies such as Maersk Air Cargo, Stryhns, Ferrosan Medical Devices and Ferring Pharmaceuticals.
He ho… Read morelds a Graduate Diploma in Business Administration (Finance & Management) from Copenhagen Business School. Prior to joining Symphogen, Michael Herbst held various management positions in finance and administration in companies such as Maersk Air Cargo, Stryhns, Ferrosan Medical Devices and Ferring Pharmaceuticals.